ALBIREO PHARMA INC's ticker is ALBO and the CUSIP is 01345P106. A total of 108 filers reported holding ALBIREO PHARMA INC in Q4 2020. The put-call ratio across all filers is 2.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $957,000 | -13.7% | 29,415 | -2.6% | 0.00% | -100.0% |
| Q2 2021 | $1,109,000 | -21.7% | 30,200 | -28.3% | 0.00% | 0.0% |
| Q1 2021 | $1,417,000 | -39.3% | 42,097 | -32.9% | 0.00% | -50.0% |
| Q4 2020 | $2,336,000 | +10518.2% | 62,757 | +10104.4% | 0.00% | – |
| Q3 2020 | $22,000 | -97.7% | 615 | -98.4% | 0.00% | -100.0% |
| Q2 2020 | $948,000 | +73.0% | 37,434 | +7.0% | 0.00% | 0.0% |
| Q1 2020 | $548,000 | -36.6% | 35,000 | +3.0% | 0.00% | 0.0% |
| Q4 2019 | $864,000 | +3500.0% | 33,995 | +2704.9% | 0.00% | – |
| Q3 2019 | $24,000 | -36.8% | 1,212 | +3.1% | 0.00% | – |
| Q2 2019 | $38,000 | -74.3% | 1,175 | -74.4% | 0.00% | – |
| Q1 2019 | $148,000 | +35.8% | 4,588 | +2.9% | 0.00% | – |
| Q4 2018 | $109,000 | -24.3% | 4,457 | +1.5% | 0.00% | – |
| Q3 2018 | $144,000 | -7.7% | 4,393 | -0.0% | 0.00% | – |
| Q2 2018 | $156,000 | +9.9% | 4,395 | +1.5% | 0.00% | – |
| Q1 2018 | $142,000 | – | 4,330 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 514,082 | $11,973,000 | 7.17% |
| Privium Fund Management B.V. | 379,117 | $8,959,000 | 1.78% |
| Birchview Capital, LP | 113,000 | $2,632,000 | 1.70% |
| Sio Capital Management, LLC | 213,913 | $4,982,000 | 1.50% |
| Perceptive Advisors | 4,720,278 | $109,936,000 | 0.85% |
| Chicago Capital, LLC | 849,239 | $19,779,000 | 0.74% |
| APOGEM CAPITAL LLC | 38,601 | $899,000 | 0.59% |
| Samsara BioCapital, LLC | 100,000 | $2,329,000 | 0.45% |
| Artal Group S.A. | 600,000 | $13,974,000 | 0.38% |
| RICE HALL JAMES & ASSOCIATES, LLC | 458,011 | $10,667,000 | 0.38% |